Refine by:
-
Letter to Congressional Committee Leadership on Child and Adolescent Mental Health and Mental Health Funding
Letter of support to urge the House Ways and Means Committee to include the Promoting Community Based Prevention Services Act (H.R. 8798) in Title IV-B in order to establish a federal definition for Family Resource Centers. -
Statement on Criminal Justice, Health Equity and Social Supports
Statement from NAMI CEO Daniel H. Gillison, Jr. on the disappointing U.S. Supreme Court ruling in City of Grants Pass v. Johnson and its consequences for people with mental illness who are unhoused. -
Statement on Criminal Justice, Health Equity and Social Supports
Statement in response to the U.S. Supreme Court’s decision in Johnson v. Grants Pass, emphasizing that the Court’s decision will have devastating consequences on the large and growing number of Americans experiencing homelessness, including people with mental health disabilities. -
Letter to Congressional Committee Leadership on Mental Health Funding and Parity
Letter to House and Senate Appropriations Committees requesting $40 million for the Employee Security Benefits Administration (EBSA) in the Labor-HHS appropriations bill for FY 2025 to review health plans’ parity compliance analyses. -
Letter to Congressional Leadership on Mental Health Funding
Letter calling on Congress to reject arbitrary funding levels for non-defense discretionary (NDD) appropriations in FY 2025, and instead fund NDD programs at a level that recognizes rising costs and the need for investments in these important programs, and keeps poison pill policy riders out of the package. -
Letter to Congressional Committee Leadership on Mental Health Funding
Letter to Labor, Health and Human Services, and Education (LHHS-Ed) appropriations subcommittees uplifting the importance of continued funding for the Certified Community Behavioral Health Clinic Expansion Grant program in the Fiscal Year 2025 LHHS-Ed Appropriations bill. -
Letter to FDA on Medication Access
Letter requesting information from the FDA so stakeholders can assist in gathering available data on clozapine prior to the next meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee. -
Letter to Biden Administration on Mental Health Funding and Social Supports
Letter requesting the Biden Administration maximize existing caregiver resources and programs within the federal government with the creation of an Office of Caregiver Health. -
Letter to Congressional Committee Leadership on Medicare and Telehealth
Letter to the House Energy and Commerce Committee leadership to urge a full committee mark up in support of the two-year delay of the six-month in-person requirement to access telemental health services under Medicare. -
Statement on Medication Access and Health Equity
Press release applauding the Supreme Court’s unanimous ruling reversing the Fifth Circuit’s decision in Alliance for Hippocratic Medicine et al. v FDA et al, expressing support of the FDA’s role in safeguarding patients, and urging the Department of Justice to continue rigorously defending that authority.